Liposomal Doxorubicin Market

SKU: DMPH2194 | Last Updated On: Sep 06 2022 | Available Formats

> Liposomal Doxorubicin Market Expected to reach a high CAGR of 6.2 % by 2029 : DataM Intelligence

Liposomal Doxorubicin Market is segmented By Product (Doxil/Caelyx, Lipodox, Myocet, Others), By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application (Kaposi Sarcoma, Leukemia, Breast Cancer, Ovarian cancer, Multiple Myeloma, Endometrial Cancer, Liver Cancer, Bone Sarcoma, Kidney Cancer, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Liposomal doxorubicin Market size was valued US$ 1,160 million in 2022 and is estimated to reach US$ 2 billion by 2029, growing at a CAGR of 6.2 % during the forecast period (2022-2029).

Liposomal Doxorubicin Market Scope

Metrics

Details

Market CAGR

6.2%

Segments Covered

By Product, By Drug Formulation, By Application, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To get a Free sample click here

Liposomal Doxorubicin is a chemotherapy drug-containing doxorubicin (Adriamycin) wrapped up in a fatty covering called a liposome. Doxorubicin blocks an enzyme called topoisomerase 2 that cancer cells need to divide and grow. Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated liposomes. These spheres keep the doxorubicin in the bloodstream longer so that more of the drug reaches the cancer cells. It is used to treat several types of cancer, including breast cancer, ovarian cancer, Kaposi's sarcoma, and multiple myeloma.

Market Dynamics

The global liposomal doxorubicin market growth is driven by the surge in prevalence of cancer globally and Increasing number of companies manufacturing doxorubicin.

The rising prevalence of cancer globally and Increasing number of companies

manufacturing doxorubicin are expected to drive market growth.

The rising number of cancer cases drives the global liposomal doxorubicin market. For instance, according to the World Health Organization (WHO), cancer accounts for 13% of deaths globally every year. Moreover, a 70% increase in cancer incidences is anticipated over the next couple of decades, and the global geriatric population is anticipated to nearly double from 12% to 22%, from 2015 to 2022. The incidence of all cancer types worldwide is anticipated to increase at a CAGR of 2.5% during 2015-2030. The mortality rate of cancers is likely to increase at a higher rate than the incidence rate during 2015-2030, at a CAGR of 2.6%.

The market growth is also estimated to boost over the forecast period due to rising product development by manufacturers and new players entering the market. For instance, in March 2019, Cytori Therapeutics, Inc. has filed a formal new drug application pre-submission request to the European Medicine Agency (EMA) for Doxorubicin Hydrochloride Cytori. This submission is the precursor to filing an Article 58 Application for a Marketing Authorization Application (MAA) via EMA’s centralized approval procedure.

Side Effects associated with doxorubicin is expected to hamper the market growth.

There are some side-effects associated with liposomal doxorubicin which are expected to hamper the market's growth over the forecast period. some of the side-effects include increased risk of getting an infection, breathlessness and looking pale, bruising, bleeding gums and nosebleeds, tiredness and weakness (fatigue) during and after treatment, soreness, redness and peeling of your hands and feet, loss of appetite and weight loss, diarrhea or constipation, among others.

Industry Analysis

The global liposomal doxorubicin market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces Analysis, Epidemiology, Regulatory Analysis, Supply Chain Analysis, Product Innovations, Unmet Needs.

Segment Analysis

Doxil/Caelyx segment is expected to hold the largest market share in global liposomal doxorubicin market

The market is segmented into Doxil/Caelyx, Lipodox, Myocet, and Others based on product type. Doxil/Caelyx segment accounted for the highest market share, owing to the rising incidence of ovarian and breast cancers. The increasing demand for Doxil or Caelyx (J&J) as a second-line treatment for ovarian carcinoma is also expected to boost its growth over the forecast period. Caelyx/Doxil is a novel pegylated liposomal formulation of the first-generation anthracycline, doxorubicin. The pharmacokinetics of this polyethylene-glycol-coated liposome is characterized by a reduced volume of distribution, a long intravascular circulating half-life and slow plasma clearance compared with free doxorubicin.

By application, the liposomal doxorubicin market is segmented into Kaposi sarcoma, leukemia, breast cancer, multiple myeloma, ovarian cancer, endometrial cancer, liver cancer, bone sarcoma, kidney cancer, and others. Among these, breast cancer accounted for the highest market share in 2018, owing to rising demand for the treatment in increasing breast cancer cases globally. According to Breastcancer.org, about 1 in 8 U.S. women (about 12%) develop invasive breast cancer over the course of their lifetime. In 2019, an estimated 268,600 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 62,930 new non-invasive (in situ) breast cancer cases. About 2,670 new cases of invasive breast cancer are expected to be diagnosed in men in 2019. A man’s lifetime risk of breast cancer is about 1 in 883. According to the American Cancer Institute, Doxorubicin is used during advanced breast cancer treatment as a chemo drug. It is observed that 3 million women diagnosed with breast cancer are currently there in the United States. Hence, an increasing burden of breast cancer leads to a rise in demand for treatment.

Geographical Analysis

North America region holds the largest market share in the global liposomal doxorubicin market

North America is dominating the global liposomal doxorubicin market, accounting for the largest market share in 2018, owing to an increasing number of cancer cases and consequently growing demand for doxorubicin in mono and combination chemotherapies. United States is the biggest market share holder of liposomal doxorubicin development and it has been allowed to import the medicine under the exercise enforcement discretion.  The huge demand of liposomal doxorubicin in the market is fueling the doxorubicin HCl liposome injections import. As of January 2019, more than 3.1 million women have a history of breast cancer in the U.S. Also, the growing number of partnerships, mergers and acquisitions for clinical trials with technologically advanced doxorubicin formulations drive the market's growth in this region.

Competitive Landscape

The liposomal doxorubicin market is highly competitive with the presence of a large number of major players. Some of the major players in the global liposomal doxorubicin market include Johnson & Johnson, SRS Pharmaceuticals Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Cadila Pharmaceuticals, Merck & Co., Cipla, Inc., Pfizer Inc., among others.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the growth of the liposomal doxorubicin market globally. For instance,

In January 2019, Celsion Corporation, an oncology drug development company, announced results from Phase I TARDOX trial of ThermoDox conducted at the University of Oxford, United Kingdom. The TARBOX trial evaluated the safety and efficacy of ThermoDox, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin, along with focused ultrasound for the treatment of liver cancer.

Global Liposomal Doxorubicin Market – Key Companies to Watch

Pfizer Inc.

Overview: Pfizer Inc. is an American multinational pharmaceutical corporation that works in biotechnology domain also. It was founded in 1849 and headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, immunology.

Products Portfolio: NYVEPRIA: It is helpful in reducing the incidence of infection, caused by febrile neutropenia, to the patients that have non-myeloid malignancies and are getting myelosuppressive anti-cancer drugs related with a clinically notable increase of febrile neutropenia.

Key Developments: In Aug 2021, Trillium Therapeutics Inc was attained for around $2.3 billion by this company along with its immuno oncology portfolio.

The global liposomal doxorubicin market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Trending Topics

Schizophrenia Drugs Market

Breast Cancer Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest